Constellation Pharmaceuticals Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Constellation Pharmaceuticals's estimated annual revenue is currently $27.7M per year.
- Constellation Pharmaceuticals received $100.0M in venture funding in April 2018.
- Constellation Pharmaceuticals's estimated revenue per employee is $201,000
- Constellation Pharmaceuticals's total funding is $423M.
- Constellation Pharmaceuticals has 138 Employees.
- Constellation Pharmaceuticals grew their employee count by 27% last year.
- Constellation Pharmaceuticals currently has 3 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Constellation Pharmaceuticals?
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Constellation Pharmaceuticals News
Wall Street analysts expect Constellation Pharmaceuticals Inc (NASDAQ:CNST) to report earnings per share of ($0.81) for the current fiscal ...
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (CNST), a clinical-stage biopharmaceutical ...
We see here that Constellation Pharmaceuticals, Inc. (:CNST) is -2.10% away from the 20-Day Simple Moving Average. Their 50-Day Simple ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Constellation Pharmaceuticals Funding
|2008-04-30||$32.0M||A||Third Rock Ventures, The Column Group||Article|
Constellation Pharmaceuticals Executive Hires
|2009-08-14||Mark A. Goldsmith||CEO||Article|
|2009-09-10||Edward E. Harlow||Chief Scientific Officer||Article|
|2010-01-11||Kerry K. Reinertsen||Chief Business Officer||Article|
|2010-01-21||Garen Bohlin||EVP Finance/Operations||Article|
|2011-01-05||James E. Audia||Chief Scientific Officer||Article|
|2011-02-02||Michael Cooper||Chief Medical Officer||Article|
|2012-03-28||Keith E. Dionne||President/CEO||Article|
|2017-07-19||Adrian Senderowicz||SVP/Chief Medical Officer||Article|
|2017-10-25||Emma Reeve||chief financial officer||Article|
|2018-11-30||Patrick Trojer||Chief Scientific Officer||Article|
|2019-03-05||Jessica Christo||Chief Product Development Officer||Article|